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Background
Solid tumors are known to be infiltrated by cells of the
immune system, and a positive prognostic value of tumor
infiltrating CD8 T cells are found in most cancers. Such
tumor infiltrating lymphocytes (TIL) can be expanded by
in vitro culture and used for adoptive cell transfer (ACT)
in the treatment of metastatic melanoma. This strategy
has led to clinical responses in about 50% of patients
with potential cures in 20%, and Center for Cancer
Immune Therapy has launched a randomized Phase III
trial using this approach. Although this is an impressive
breakthrough in the treatment of metastatic melanoma,
80% of patients still succumb to disease, and 50% have
no benefit from treatment. Thus, TILs are quite often
unable to fully control and eliminate the cancer, and
inappropriate regulation of immune mechanisms is
thought to play a role in this. A number of tumor sup-
pressor mechanisms have already been described, includ-
ing tumors inducing intrinsic inhibitory pathways in
TILs. This renders TILs less active and tumors can
hereby avoid immune recognition and destruction.
Methods
In the current project, we want to genetically engineer
T cells to block inhibitory pathways prior to ACT. Taking
advantage of the recently developed CRISPR/Cas9 tech-
nology, genes associated with inhibitory pathways will
be deleted from the genome of tumor specific T cells.
These T cells will then be tested for in vivo functionality
in the tumor microenvironment using a humanized
mouse model. We believe that success in genetically
engineering T cells to elicit sustained functionality in a
suppressive tumor microenvironment would be of great
importance for the further development of ACT.
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